NEKTAR THERAPEUTICS

Form 4 March 13, 2006

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

Issuer

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Expires: 2005 Estimated average burden hours per 0.5

OMB APPROVAL

3235-0287

January 31,

response...

if no longer subject to Section 16. Form 4 or Form 5

Check this box

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1(b).

(Last)

1. Name and Address of Reporting Person * Elam Nevan C

(First)

2. Issuer Name and Ticker or Trading

Symbol

NEKTAR THERAPEUTICS

[NKTR]

(Middle) 3. Date of Earliest Transaction

> (Month/Day/Year) 03/10/2006

(Check all applicable) Director 10% Owner

5. Relationship of Reporting Person(s) to

Other (specify X_ Officer (give title below)

C/O NEKTAR THERAPEUTICS, 150

INDUSTRIAL ROAD

(Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

General Counsel and Secretary

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

SAN CARLOS, CA 94070

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)

2. Transaction Date 2A. Deemed (Month/Day/Year)

Execution Date, if

(Month/Day/Year)

3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5)

5. Amount of Securities Beneficially Owned Following Reported

6. Ownership 7. Nature of Form: Direct Indirect (D) or Indirect Beneficial (Instr. 4)

Transaction(s)

Ownership (Instr. 4)

(A)

(Instr. 3 and 4)

Code V Amount (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: NEKTAR THERAPEUTICS - Form 4

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	. 5. Number 6. Date Exe		cisable and 7. Title ar		d Amount of	8. Pr
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction Derivative Code Securities		Expiration Date		Underlying Securities		Deri
Security	or Exercise		any			(Month/Day/Year)		(Instr. 3 and 4)		Secu
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired					(Inst
	Derivative				(A) or					
	Security				Disposed of					
					(D)					
					(Instr. 3, 4,					
					and 5)					
				Code V	(A) (D)	Date	Expiration	Title	Amount	
				Couc v	(11) (D)	Exercisable	Date	Title	or	
						LACICISADIC	Date		Number	
									of	
									Shares	
									Shales	
Restricted Stock Unit	\$ 0.01	03/10/2006		A	7,000	<u>(1)</u>	(2)	Common Stock	7,000	\$ (
Stock Ullit								Stock		

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Elam Nevan C C/O NEKTAR THERAPEUTICS 150 INDUSTRIAL ROAD SAN CARLOS, CA 94070

General Counsel and Secretary

Signatures

/s/ Nevan C. 03/13/2006

**Signature of Date
Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The shares of Common Stock are issued upon the vesting of restricted stock units granted to the holder. The restricted stock units (RSUs) vest based on the Company achieving certain corporate performance milestones as follows: 1/5th of the RSUs vest based on achievement

- (1) of a corporate goal related to the total number of Exubera Inhalers shipment; 2/5th vest based on achievement of a corporate goal related to Exubera quarterly royalty revenue; and 2/5th vest based on achievement of a corporate goal related to regulatory progress of the Companys proprietary products programs.
- (2) Not Applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2